Outsourced Pharma Capabilities Update June 2026: Antibody Drug Conjugates

In this Capabilities Update, CDMOs will share how they support ADC programs from early development through clinical and commercial manufacturing. By attending this digital event, you will gain insight into the technical expertise, scalability, and regulatory considerations required to advance ADCs efficiently.

The presentations will also highlight key considerations when evaluating CDMO partners, including experience with complex conjugation processes and the ability to deliver integrated development and manufacturing support.

Whether you are initiating a new ADC program or refining existing processes, this session provides a clearer understanding of how to select a partner aligned with your program’s technical and operational needs.